HealthEquity, Inc.
NASDAQ:HQYMedical - Healthcare Information Services
-$0.54 today
- Market cap
- $8.05B
- Beta
- 0.21
- P/E (TTM)
- 31.4
- EPS (TTM)
- $2.73
Volume 1.29M
Average 0.98M
HQY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
HealthEquity, Inc.NASDAQ: HQY
EBITDA · Q2 FY2027 · quarter ended Jul 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2027 EBITDA of $142.43M rose 8.3% year over year, behind the +22.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 8.3% from the prior quarter. Over 3 fiscal years it compounded at +41.8% a year.
Context
- EBITDA amounted to 37.2% of revenue in FY2026, up 9.1 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of $761.8M (+55.7%) for the fiscal year ending Jan 2027, a step up from the +44.9% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJul 2026
- $142.43M+8.3% QoQ
- Last fiscal yearJan 2026
- $489.22M+44.9% YoY
- LTMJul 2026
- $495.07M+22.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.3% | +63.6% | +55.3 pp |
| 1 year | +44.9% | +55.7% | +10.8 pp |
| 3-year CAGR | +41.8% | +19.9% | -21.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2026
- 489.22M USD
- Year-over-year change
- +44.9%
- 4-year CAGR
- +47.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 489.22M | +44.9% |
| FY2025 | 2025-01-31 | 337.54M | +19.5% |
| FY2024 | 2024-01-31 | 282.42M | +64.6% |
| FY2023 | 2023-01-31 | 171.53M | +66.6% |
| FY2022 | 2022-01-31 | 102.97M | — |
EBITDA vs competitors
How HQY compares with its peers on the latest reported figures
- HQY's LTM Jul 2026 EBITDA of $495.07M is the 2nd highest of the 8 companies compared; the peer median is $42.42M.
- Its year-over-year change of +22.1% is the 5th highest of 8, against a peer median of +56.9%.
- EBITDA amounts to 36.3% of revenue for HQY, versus a peer median of 22.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $517.45M | +198.9% | +44.3% | 52.9% |
| LTM Jul 2026 | $495.07M | +22.1% | +41.8% | 36.3% | |
| LTM Jun 2026 | $432.42M | +15.2% | +12.7% | 35.9% | |
| LTM Mar 2026 | $124.69M | -1.1% | +1.7% | 10.2% | |
| LTM Apr 2026 | $42.42M | +563.3% | — | 8.6% | |
| LTM Mar 2026 | $28.3M | +17.2% | +10.4% | 22.8% | |
| LTM Mar 2026 | $491K | +101.7% | — | 0.2% | |
| LTM Mar 2026 | -$53.01M | +56.9% | — | 22.3% | |
| Peer median (excluding HQY) | $42.42M | +56.9% | +11.5% | 22.3% | |
Competitors are the stored peer set for HQY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 756.56M | 861.75M | 999.59M | 1.2B | 1.31B |
| Cost of Revenue | 415.64M | 466.24M | 469.71M | 507.19M | 400.31M |
| Gross Profit | 340.92M | 395.51M | 529.87M | 692.58M | 913.12M |
| Gross Margin | 45.1% | 45.9% | 53.0% | 57.7% | 69.5% |
| Research & Development | 157.36M | 193.38M | 218.81M | 239.51M | 262.51M |
| Selling, General & Admin | 142.98M | 164.48M | 182.93M | 223M | 328.15M |
| Operating Expenses | 300.35M | 357.85M | 401.74M | 462.51M | 590.66M |
| Depreciation & Amortization | 137.19M | 161.2M | 153.08M | 162.45M | 154.66M |
| EBITDA | 102.97M | 171.53M | 282.42M | 337.54M | 489.22M |
| EBITDA Margin | 13.6% | 19.9% | 28.3% | 28.1% | 37.2% |
| Operating Income | 40.57M | 37.65M | 128.13M | 230.07M | 322.46M |
| Operating Margin | 5.4% | 4.4% | 12.8% | 19.2% | 24.6% |
| Interest Income | 1.5M | 1.76M | 12.14M | 13.91M | 12.11M |
| Interest Expense | 36.57M | 48.42M | 55.46M | 60.63M | 57.13M |
| Other Income / Expenses | (107.31M) | (75.75M) | (53.09M) | (114.04M) | (45.02M) |
| Income Before Tax | (66.74M) | (38.1M) | 75.04M | 116.03M | 277.43M |
| Pre-Tax Margin | -8.8% | -4.4% | 7.5% | 9.7% | 21.1% |
| Income Tax Expense | (22.45M) | (11.95M) | 19.33M | 19.33M | 62.23M |
| Net Income | (44.29M) | (26.14M) | 55.71M | 96.7M | 215.2M |
| Net Margin | -5.9% | -3.0% | 5.6% | 8.1% | 16.4% |
| EPS (Basic) | (0.53) | (0.31) | 0.65 | 1.11 | 2.50 |
| EPS (Diluted) | (0.53) | (0.31) | 0.64 | 1.09 | 2.46 |
| Weighted Avg Shares | 83.13M | 84.44M | 85.56M | 86.87M | 86.13M |
| Weighted Avg Shares (Diluted) | 83.13M | 84.44M | 86.96M | 88.83M | 87.47M |
HealthEquity, Inc.
NASDAQ:HQY
Intrinsic Alpha fair value
Locked
Current Price
$97.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.